Press Release | NeoGenomics Laboratories

May 10, 2022

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting

May 9, 2022

NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary

May 5, 2022

NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference

April 27, 2022

NeoGenomics Reports Revenue of $117 Million in the First Quarter

April 25, 2022

NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay

April 11, 2022

NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR™ Assay MRD Assay at AACR 2022

April 11, 2022

NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D

April 8, 2022

NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients